Beijing SL Pharmaceutical. 

Operating both domestically within the People's Republic of China and across international markets, Beijing SL Pharmaceutical Co., Ltd. is a biopharmaceutical firm dedicated to the research, development, manufacturing, and commercialization of genetic engineering-based pharmaceuticals and associated medicinal products. Its extensive portfolio of finished pharmaceutical products encompasses a diverse range of medications, including but not limited to, temozolomide, arsenic trioxide, lenalidomide, docetaxel, paclitaxel, recombinant human granulocyte colony-stimulating factor (filgrastim), recombinant human interleukin-11, recombinant human interleukin-2, thymopentin, vinorelbine bitartrate, hydroxyl-camptothecine, nimustine hydrochloride, asparaginase, PEG L-asparaginase, calcium foliate, recombinant human basic fibroblast growth factor, ciclosporin, mycophenolate mofetil dispersible, ornidazole, adefovir dipivoxil, levofloxacin hydrochloride, azithromycin, ribavirin, tenofovir disoproxil fumarate, valacylovir hydrochloride, lysozyme, stavudine, tropisetron hydrochloride, granisetron hydrochloride, omeprazole, ademetionine 1,4-butanedisulfonate, glutathione, enoxaparin sodium, coenzyme complex, ginkgo biloba extract, simvastatin, telmisartan, naftopidil, nicergoline, zaleplon, cytidine disodium triphosphate, febuxostat, risedronate sodium, loratadine dispersible, somatostatin, octreotide acetate, calcitonin (salmon), the combination of paracetamol and tramadol hydrochloride, and etodolac. Furthermore, the company supplies active pharmaceutical ingredients (APIs). Established in Beijing, People's Republic of China, in 1994, the enterprise initially operated under the name Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd. before officially adopting its current designation, Beijing SL Pharmaceutical Co., Ltd., in 1998.